Anti-cancer drug could be anti-flu too

Although DMXAA was developed to fight cancer, researchers have found the anti-tumor agent has promising results in flu vaccines via an interferon response.

In a study published in the Journal of Leukocyte Biology, scientists administered two doses of the DMXAA-infused vaccine to infected rats, one dose within three hours of infection and one two days later. Not only did the mice sustain a more mild illness due to the interferon response, the DMXAA vaccine was effective against Tamiflu-resistant strains as well.

"H1N1 was a wake-up call that the flu remains a very serious disease, regardless of how 'common' we may think it is," said E. John Wherry, deputy editor of the Journal of Leukocyte Biology, in a release. "Every year this virus mutates, and history has shown us that new, very dangerous strains of this virus will continue to emerge. New drugs like this one that can combat this virus--especially drugs that are effective against newly emerging strains-may prove to be lifesaving for millions of people around the world."

- get the release

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.